[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354023-105":59,"doc-detail-354023-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","a-retrospective-analysis-of-taxane-based-chemotherapy-in-small-bowel-adenocarcinoma","A retrospective analysis of taxane-based chemotherapy in small bowel adenocarcinoma","","Background: Small bowel adenocarcinoma (SBA) is molecularly distinct from colorectal and gastric cancers, yet treatment often follows colorectal paradigms. Methods: A retrospective review evaluated SBA patients receiving taxane-based chemotherapy at MD Anderson from 1994–2024, requiring pathologic confirmation and ≥1 treatment cycle with response assessment. Survival was analyzed using Kaplan–Meier and Cox models. Results: Seventy patients were identified; overall response was 24%, mTTP 3.1 months, and mOS 8.7 months. TP53 mutation predicted poorer outcomes. Conclusion: Taxane-based therapy shows clinical activity in metastatic SBA and warrants prospective study.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-retrospective-analysis-of-taxane-based-chemotherapy-in-small-bowel-adenocarcinoma/354023/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-retrospective-analysis-of-taxane-based-chemotherapy-in-small-bowel-adenocarcinoma/354023.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What was the purpose of this retrospective study on SBA?","Question",{"text":113,"@type":114},"To evaluate the activity of taxane-based therapy in small bowel adenocarcinoma using the largest cohort reported to date.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were patients selected and how was survival analyzed?",{"text":118,"@type":114},"Patients had pathologic confirmation, received more than one chemotherapy cycle, and had tumor response evaluation; survival outcomes were analyzed with Kaplan–Meier curves and Cox proportional hazards models.",{"name":120,"@type":111,"acceptedAnswer":121},"What key efficacy results were reported for taxane-based treatment?",{"text":122,"@type":114},"The overall response rate was 24%, median time to progression was 3.1 months, and median overall survival was 8.7 months.",{"name":124,"@type":111,"acceptedAnswer":125},"How did TP53 mutation status relate to treatment outcomes?",{"text":126,"@type":114},"TP53-mutated tumors had lower response and worse survival outcomes, and multivariable analysis indicated TP53 mutation predicted worse results.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},354023,1790182428,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","A retrospective analysis of taxane-based chemotherapy in small bowel adenocarcinoma  \nMir Lim1,*,†, , Nikhil Grandhi1,†, Preksha Shah1, Kanwal Raghav1, Victoria Serpas1, Maria Pia Morelli1, Katrina Pedersen2, Aparna Kalyan3, Mohamed Salem4, Ryan Huey1, John Paul Shen1, Huamin Wang 5, Hua Wang1, Anjali Vinocha1, Jane Thomas1, , Robert Wolff1, , Michael J. Overman1  \n1 Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States  \n2 Department of Medical Oncology, Mayo Comprehensive Cancer Center, Rochester, NY 55905, United States  \n3 Division of Hematology Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, United States 4 Department of Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, United States  \n5 Department of Pathology, The University of Texas MD Anderson Cancer Center, Charlotte, NC 77030, United States  \n*Corresponding author: Mir Lim, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States ([MLim1@mdanderson.org](MLim1@mdanderson.org)) .  \n†Shared co-first authorship.  \nAbstract  \nBackground: Small bowel adenocarcinoma (SBA) is molecularly distinct from colorectal and gastric cancers, yet treatment typically parallels colorectal cancer. We evaluated the activity of taxane-based therapy in the largest SBA cohort to date. Methods: We retrospectively reviewed SBA patients treated with taxane-based chemotherapy at MD Anderson Cancer Center from 1994 to 2024. Eligible patients had pathologic confirmation, received >1 treatment cycle, and had tumor response evaluation. Survival analyses were analyzed using Kaplan–Meier and Cox proportional hazard models.  \nResults: Seventy patients were identified. Median age was 57, and 59% were male. Primary sites were duodenum (44%), jejunum (34%), and ileum (16%). Metastatic sites included peritoneum (39%) and liver (31%). Common mutations were TP53 (63%), KRAS (47%), SMAD4 (24%), and APC (15%). Taxanes were administered as single agents (29%) or in combination (71%), most often in second- (40%) or third-line (33%) settings. Overall response rate was 24%. Median time to progression (mTTP) was 3.1 months (95% CI: 2.0-4.2) and median overall survival (mOS) was 8.7 months (95% CI: 7.4-10.1). Efficacy did not differ by treatment line, regimen type, or tumor site, but was significantly associated with TP53 status; response rate was 20% in TP53-mutated vs 45% in wild-type (P = .009), with mTTP 2.5 vs 4.9 months (P = .009) and mOS 7.3 vs 10.6 months (P = .002). On multivariable analysis, TP53 mutation predicted worse outcomes.  \nConclusion: Taxane-based therapy demonstrated activity in metastatic SBA, with 24% response and 3.1-month mTTP. TP53 mutation may be a negative predictive marker for taxane efficacy. These findings support prospective investigation in metastatic SBA.  \nKey words: taxane; SBA; TP53; chemotherapy  \nImplications for Practice  \nThis is the largest cohort of patients with metastatic SBA treated with taxane-based chemotherapy. Taxane-based chemotherapy demonstrates a meaningful clinical benefit with a response rate of 24%, median TTP of 3.1 months, and median OS of 8.7 months. TP53 mutations may represent a negative predictive marker for taxane-based chemotherapy.  \nReceived: September 29, 2025. Accepted: March 11, 2026 © The Author(s) 2026. Published by Oxford University Press.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.  \nIntroduction  \nSmall bowel adenocarcinoma (SBA) is a rare cancer accounti","cbCail3Hf05Whk2l","https://ap.wps.com/l/cbCail3Hf05Whk2l","pdf",944780,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n## Implications for Practice\n# Introduction","[{\"question\":\"What was the purpose of this retrospective study on SBA?\",\"answer\":\"To evaluate the activity of taxane-based therapy in small bowel adenocarcinoma using the largest cohort reported to date.\"},{\"question\":\"How were patients selected and how was survival analyzed?\",\"answer\":\"Patients had pathologic confirmation, received more than one chemotherapy cycle, and had tumor response evaluation; survival outcomes were analyzed with Kaplan–Meier curves and Cox proportional hazards models.\"},{\"question\":\"What key efficacy results were reported for taxane-based treatment?\",\"answer\":\"The overall response rate was 24%, median time to progression was 3.1 months, and median overall survival was 8.7 months.\"},{\"question\":\"How did TP53 mutation status relate to treatment outcomes?\",\"answer\":\"TP53-mutated tumors had lower response and worse survival outcomes, and multivariable analysis indicated TP53 mutation predicted worse results.\"}]","A retrospective analysis of taxane-based chemotherapy in small bowel adenocarcinoma | PDF",1790108495,18,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58cba2458ec88b9b43c99c0a8c6efbfe.webp",983,1291,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58dc5bcbcc239664856111a0744c7909.webp",982,1290,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d0dbbcba606478a559fccd35dacd93cb.webp",981,1289,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5b672c44f7a29907e6e4fede92caa18.webp",980,1287]